PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas M Grieco, M Santoro, MT Berlingieri, RM Melillo, R Donghi, I Bongarzone, ... Cell 60 (4), 557-563, 1990 | 1147 | 1990 |
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer G Viglietto, ML Motti, P Bruni, RM Melillo, A D'alessio, D Califano, F Vinci, ... Nature medicine 8 (10), 1136-1144, 2002 | 890 | 2002 |
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. M Santoro, F Carlomagno, ID Hay, MA Herrmann, M Grieco, R Melillo, ... The Journal of clinical investigation 89 (5), 1517-1522, 1992 | 477 | 1992 |
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells RM Melillo, MD Castellone, V Guarino, V De Falco, AM Cirafici, ... The Journal of clinical investigation 115 (4), 1068-1081, 2005 | 422 | 2005 |
Thyroid cancer and inflammation V Guarino, MD Castellone, E Avilla, RM Melillo Molecular and cellular endocrinology 321 (1), 94-102, 2010 | 287 | 2010 |
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity M Fedele, R Visone, I De Martino, G Troncone, D Palmieri, S Battista, ... Cancer cell 9 (6), 459-471, 2006 | 285 | 2006 |
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture M Santoro, RM Melillo, A Fusco European Journal of Endocrinology 155 (5), 645-653, 2006 | 261 | 2006 |
Minireview: RET: normal and abnormal functions M Santoro, RM Melillo, F Carlomagno, G Vecchio, A Fusco Endocrinology 145 (12), 5448-5451, 2004 | 224 | 2004 |
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma G Salvatore, TC Nappi, P Salerno, Y Jiang, C Garbi, C Ugolini, P Miccoli, ... Cancer research 67 (21), 10148-10158, 2007 | 222 | 2007 |
Mast cells have a protumorigenic role in human thyroid cancer RM Melillo, V Guarino, E Avilla, MR Galdiero, F Liotti, N Prevete, ... Oncogene 29 (47), 6203-6215, 2010 | 221 | 2010 |
Molecular mechanisms of RET activation in human cancer M Santoro, RM Melillo, F Carlomagno, A Fusco, G Vecchio Annals of the New York Academy of Sciences 963 (1), 116-121, 2002 | 219 | 2002 |
BRAF is a therapeutic target in aggressive thyroid carcinoma G Salvatore, V De Falco, P Salerno, TC Nappi, S Pepe, G Troncone, ... Clinical Cancer Research 12 (5), 1623-1629, 2006 | 211 | 2006 |
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway C Visciano, F Liotti, N Prevete, G Cali, R Franco, F Collina, A de Paulis, ... Oncogene 34 (40), 5175-5186, 2015 | 202 | 2015 |
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas MD Castellone, V Guarino, V De Falco, F Carlomagno, F Basolo, ... Oncogene 23 (35), 5958-5967, 2004 | 181 | 2004 |
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade RM Melillo, M Santoro, SH Ong, M Billaud, A Fusco, YR Hadari, ... Molecular and Cellular Biology, 2001 | 166 | 2001 |
The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line M Santoro, RM Melillo, M Grieco, MT Berlingieri, G Vecchio, A Fusco Cell growth and differentiation 4, 77-77, 1993 | 165 | 1993 |
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret M Chiariello, R Visconti, F Carlomagno, RM Melillo, C Bucci, ... Oncogene 16 (19), 2435-2445, 1998 | 159 | 1998 |
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. F Carlomagno, G De Vita, MT Berlingieri, V De Franciscis, RM Melillo, ... The EMBO journal 15 (11), 2717-2725, 1996 | 155 | 1996 |
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer V De Falco, V Guarino, E Avilla, MD Castellone, P Salerno, G Salvatore, ... Cancer research 67 (24), 11821-11829, 2007 | 144 | 2007 |
Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2) F Carlomagno, D Vitagliano, T Guida, F Basolo, MD Castellone, ... The Journal of Clinical Endocrinology & Metabolism 88 (4), 1897-1902, 2003 | 143 | 2003 |